Sanofi and GSK announced on 14 April 2020 that they will work together on the velopment of a new, adjuvanted vaccine for COVID-19. As the world’s leading vaccine manufacturer, our number one focus is to help velop a vaccine.
Sanofi and GSK announced on 14 April 2020 that they will work together on the velopment of a new, adjuvanted vaccine for COVID-19. As the world’s leading vaccine manufacturer, our number one focus is to help velop a vaccine.
The collaboration for the first time brings together the scientific and manufacturing expertise and resources of two global scale vaccines specialists to address the urgent global need for a vaccine to protect people from this disease.
The two companies expect a candidate vaccine to enter clinical trials in the second half of 2020 and, if successful and subject to regulatory consirations, aim to complete the velopment required for availability by the second half of 2021.
